Albert Bourla, the head of pharmaceutical giant Pfizer, which is among the companies developing a coronavirus vaccine, said Sunday there is a “good chance” the company will know whether its vaccine works by the end of October.
The drugmaker should have key data from its late-stage trial for the Food and Drug Administration by the end of October, Bourla said during an interview on CBS’ “Face the Nation.” If the FDA approves the vaccine, the company is prepared to distribute “hundreds of thousands of doses,” he said.
Pfizer is regarded as being among the top three contenders in developing a successful COVID-19 vaccine. The pharmaceutical giant, along with Moderna (MRNA) and AstraZeneca (AZN), are all in the late-stage testing phase.
On September 8, 2020, nine drug companies, including Pfizer, released a joint statement to calm public fears over a vaccine being approved before being adequately tested. They pledged to prioritise safety and “uphold the integrity of the scientific process” as they each developed vaccines.
The announcement follows US president Donald Trump publicly putting pressure on the FDA to fast track a vaccine.
Pfizer Inc. said it’s likely the U.S. will deploy a Covid-19 shot before the end of the year. AstraZeneca Plc restarted testing after its vaccine trial was halted last week. Global coronavirus cases surpassed 29 million and deaths exceed 924,000. Sam Fazeli of Bloomberg Intelligence has the latest on “Bloomberg Markets: European Open.”